Audentes Therapeutics Form 3 Initial statement of insider ownership

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Audentes Therapeutics, Inc.

(Last)

(First)

(Middle)

600 CALIFORNIA STREET, 17TH FLOOR

(Street)

SAN FRANCISCO

94108

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/21/2022

3. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,266,342	D⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

1. Name and Address of Reporting Person^*

Audentes Therapeutics, Inc.

(Last)

(First)

(Middle)

600 CALIFORNIA STREET, 17TH FLOOR

(Street)

SAN FRANCISCO

94108

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Astellas Pharma Inc.

(Last)

(First)

(Middle)

2-5-1, NIHONBASHI-HONCHO, CHUO-KU

(Street)

TOKYO

103-8411

(City)

(State)

(Zip)

Explanation of Responses:

1. The securities are directly held by Audentes Therapeutics, Inc., a Delaware corporation, ("Audentes") a wholly owned direct subsidiary of Astellas US Holding, Inc., a Delaware corporation, ("Astellas US") which is in turn a wholly owned direct subsidiary of Astellas Pharma Inc., a corporation established under the laws of Japan ("Astellas"). Under SEC rules and regulations, each of Astellas and Astellas US may be deemed to have indirect beneficial ownership of the shares held by Audentes, which has direct beneficial ownership.

Remarks:

Exhibit List Exhibit 24.1 - Power of Attorney (Astellas) Exhibit 24.2 - Power of Attorney (Audentes)

	/s/ Chad Diehl, Attorney-in-Fact, Astellas	10/31/2022
	/s/ Chad Diehl, Attorney-in-Fact, Audentes	10/31/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Audentes Therapeutics Form 3Initial statement of insider ownership